The Food and Drug Administration (FDA) has approved the combination sulopenem etzadroxil and probenecid, an oral antibiotic, to treat bacterial urinary tract infections (UTI) in adult women caused by Escherichia coli, Klebsiella pneumoniae, or Proteus mirabilis. Manufacturer Iterum Therapeutics anticipates a commercial launch for the drug, branded as Orlynvah, in 2025, according to Reuters. The oral drug is taken twice daily for 5 days and can be used to treat uncomplicated UTIs in women who have few or no oral antibacterial treatment options. It is not indicated for the primary or step-down treatment of complicated UTI or complicated intra-abdominal infections, according to FDA. Complete indications and usage information can be found on the company’s website.
More options: In May, FDA also approved the oral antibiotic pivmecillinam for treating uncomplicated UTIs. Marketed as Pivya, pivmecillinam can treat UTIs caused by Escherichia coli, Proteus mirabilis and Staphylococcus saprophyticus.